ARKG rose approximately 13% over the past 30 days, driven primarily by gains in key genomics and biotechnology holdings amid improving sector sentiment. Over the past quarter, ARKG advanced roughly 28%, reflecting broader recovery in healthcare innovation themes and positive momentum in gene-editing and sequencing companies.

XLV is in a short-term downtrend with a strong sell technical rating from moving averages and oscillators. Price is consolidating near recent lows around 144-145, below key moving averages including the 20-day at 145.94 and 200-day at 147.23.

IHI declined approximately -8.5% over the past 30 days amid softer demand for medical devices and broader healthcare sector pressures. Over the past quarter, the ETF fell around -15%, underperforming the broader health category due to valuation adjustments and muted procedural volumes.

Top hedge funds like Millennium, Citadel, and Bridgewater showed limited direct accumulation of penny stocks in Q4 2025 13F filings, but rotations into biotech, energy, and defense sectors highlight indirect interest in low-priced plays under $5. New entries and increased positions focused on volatile sectors like biotech (e.g., ABCL) and energy (e.g., AMPY), with full exits from overvalued names signaling a hunt for undervalued pennies amid market uncertainty.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC), a clinical-stage biopharmaceutical company focused on innovative cancer therapies, has captured the attention of investors with a staggering 251.95% stock price surge over the past five trading days as of July 22, 2025, accompanied by an average daily trading volume of 1 million shares.

Tickeron launches AI-powered Stock Picker robots to assist hedge fund managers with sector rotation, growth-focused small-cap stocks, and strategic risk management. Using proprietary FLMs, Stock Pickers offer quant-driven signals and adaptive strategies for long-term growth and investment

The current health crisis has created a lot of buzz around the biotech sector as several companies from the sector are working on potential vaccines against the COVID-19 virus.Many of the companies are overvalued at this time, but the fundamentals of many are really good. I looked at the SPDR S&P Biotech ETF (NYSE: XBI) and its components.

The biotech sector has been trending lower for the last five months, but has seen a bit of a rally over the last few weeks as investors appear to be making a shift from growth stocks to value stocks.Because of this rotation, many stocks in the sector are in overbought territory, at least on the daily charts.

The healthcare sector has been lagging the nine other main sectors since the beginning of 2019.The sector has been in the political spotlight to some degree as politicians on both sides of the aisle have been pointing at drug costs as a problem. One particular exchange-traded fund that caught my eye was the iShares Nasdaq Biotechnology ETF (Nasdaq: IBB).

Are You? Also in this newsletter Healthcare sector ETF (XLV) trending lower since November A.I.It means evaluating myriad variables – post-retirement lifestyle, where to retire, cost of living, the rate of inflation, and more – then formulating a plan that considers current earnings and standard of living, in addition to… Read More… —————————————————————————————— Healthcare sector ETF (XLV) trending lower since November The overall market recovered from the selling that hit in December and that led the S&P 500 to a new all-time high on May 1.

The overall market recovered from the selling that hit in December and that led the S&P 500 to a new all-time high on May 1.The Healthcare Select Sector SPDR (NYSE: XLV) peaked just above $90 back in November and it has yet to get back to that point. In fact, if you connect the high from November with the highs from March and April, you can see the downward sloped trend line the ETF has formed.

Five U.S. states filed lawsuits accusing Purdue Pharma of illegally marketing and selling opioids, escalating the wave of litigation over a nationwide abuse epidemic. Iowa, Kansas, Maryland, West Virginia and Wisconsin joined 39 states to file lawsuits targeting Purdue Pharma and its leaders, including former president Richard Sackler and his family.  Officials accused Purdue Pharma of repeatedly making false and deceptive claims that opioids, including OxyContin, were safe for a wide range of patients seeking to reduce pain.  Purdue Pharma called the new lawsuits “misleading attacks.” “These complaints are part of a continuing effort to try these cases in the court of public opinion rather than the justice system,” the Stamford, Connecticut-based company said.

The Department of Health and Human Services announced a new policy to improve transparency in the pharmaceutical industry. Starting this summer, TV commercials for prescription drugs covered by Medicaid or Medicare must mention the list price if it exceeds $35 for the standard treatment course or monthly supply. The policy has no enforcement mechanism but depends on companies suing rivals that violate the standard. The HHS will also publish a list of drugs with non-compliant ads. “Patients who are struggling with high drug costs are in that position because of the high list prices that drug companies set,” HHS Secretary Alex Azar said in a press release.“Making those prices more transparent is a significant step in President Trump’s efforts to reform our prescription drug markets and put patients in charge of their own healthcare.”

President Donald Trump's proposed budget might make it easier for seniors to save for health-care costs on a tax-free basis. The proposal would allow beneficiaries to make tax-deductible contributions to health savings accounts "associated with high-deductible health plans offered by their employers or a Medicare Advantage plan." Current law keeps Medicare beneficiaries from making new contributions to HSAs, but they can still use money in the account to pay for health-care expenses.  HSAs allow you to save money either on a pre-tax or tax-deductible basis, have it accumulate interest free of taxes and then make tax-free withdrawals to pay for qualified medical expenses.They are offered in conjunction with high-deductible health plans, which come with a deductible of at least $1,350 for self-only coverage or $2,700 for family plans in 2019. In 2019, account holders can contribute up to $3,500 if they have self-only health coverage ($7,000 for family plans), plus a

Hospital groups are objecting strongly to billions of dollars in proposed Medicare and Medicaid payment cuts in President Donald Trump's budget. Two major hospital trade groups did not mince words in blog posts Monday by their leaders. Chip Kahn, president of the Federation of American Hospitals, is calling proposed Medicare cuts "arbitrary and blunt," adding, "the impact on care for seniors would be devastating." American Hospital Association President Rick Pollack says the budget raises "serious concerns about how hospitals and health systems can ensure they serve as the safety net" for patients. The budget includes a range of hospital cuts over 10 years, including reduced reimbursements for uncompensated care and lower rates for outpatient departments.

Anchiano Therapeutics Ltd. is expected to issue 2.4 million shares at $14.55 each Tuesday on the Nasdaq.The company is developing a single biologic candidate to treat bladder and other cancers. Anchiano has had promising trial results, strong existing investor support of the IPO, and a low IPO valuation, but the early stage of its development may mean the IPO is more appropriate for high risk, long-term life science investors.

In last year's volatile market, healthcare remained a strong investment for those seeking growth.As we start 2019, healthcare remains a favorite sector of Wall Street, according to a report in Reuters.  Supporters say the healthcare sector has reasonable valuations, strong balance sheets and dividend payments. For 2019, healthcare companies in the S&P 500 are expected to increase earnings by 7.5 percent, ahead of the 6.3 percent growth estimated for S&P 500 companies overall, according to IBES data from Refinitiv.

A new study by the Centers for Medicare and Medicaid Services says Americans paid $3.5 trillion on healthcare in 2017, which amounts to $10,739 per person." Private health insurance had the highest spending with an increase of 4.2 percent to $1.2 trillion, in 2017.

Shares of Johnson & Johnson JNJ, +0.03% fell 3.3% in afternoon trade, enough to pace declines among its health care peers and among the Dow Jones Industrial Average's DJIA, +1.46% components, after reports that an appeals court ruled that J&J can't block sales of generic Zytiga while the company appeals the overturning of a Zytiga patent.  READ MORE...

Principia Biopharma continued its impressive progress with its recent initial public offering on September 14, 2018.Principia Biopharma (Nasdaq: PRNB) has developed three drug candidates in immunology, central nervous system disorders, and oncology. The company is utilizing 'Tailored Covalency,' its proprietary drug discovery platform, to discover new drugs that combine the dosing ability of an oral small molecule drug with the specificity of an antibody. Standard small molecule drugs have a short duration of time that the drug binds to its target, called residence time, that require dosing regimens to maintain target concentration levels in the blood to get the desired result. Principia has designed its drugs to remain bound to the target, and clear the body rapidly, to optimize residence time.